A longitudinal, prospective study to assess retinal layers volume changes in ocrelizumab-treated PPMS patients by means of Optical coherence tomography
Latest Information Update: 15 Dec 2021
Price :
$35 *
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 15 Dec 2021 New trial record